Medtronic recently completed its acquisition of Affera, a deal designed to expand Medtronic's cardiac ablation portfolio.
Affera is developing technology to treat patients with cardiac arrhythmias such as atrial fibrillation. This includes a cardiac mapping and navigation platform that encompasses a diagnostic focal-pulsed field and radiofrequency ablation product.
Medtronic said that through the acquisition, Affera's Affera Prism-1 technology will be compatible with therapeutic catheters and technologies from Medtronic and other companies. The company also gains the Sphere-9 cardiac diagnostic and ablation catheter, which allows for the creation of electroanatomical maps and delivers radio frequency and pulsed-field cardiac ablation therapies.
Additional Affera pipeline products such as the Arc-10 coronary sinus diagnostic catheter and Sphere PVI ablation catheter are also included in the deal.
